Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

During morning rounds on hospital day 5, a 65-year-old male patient is assessed. He was admitted for community-acquired pneumonia and has a medical history significant for a mechanical mitral valve replacement performed 4 years ago. His home medications include warfarin and metoprolol. Upon admission, empiric treatment was initiated with intravenous ceftriaxone and oral azithromycin. On hospital day 3, this regimen was changed to oral levofloxacin based on sputum culture susceptibilities.

His respiratory symptoms have largely resolved. When interviewed today, the patient denies any hemoptysis, hematuria, melena, or easy bruising. Vital signs are within normal limits. Physical examination demonstrates a crisp mechanical first heart sound and lungs that are clear to auscultation bilaterally. There is no clinical evidence of petechiae or mucosal bleeding.

Morning laboratory studies show:
- Hemoglobin: 13.5 g/dL
- Platelet count: 210,000/mm³
- Serum creatinine: 1.1 mg/dL
- International Normalized Ratio (INR): 7.4 (Admission INR: 2.8)

Which of the following is the most appropriate next step in the management of this patient's anticoagulation?

  1. Withhold warfarin and monitor the International Normalized Ratio dailyCevap
  2. B
    Withhold warfarin and administer oral phytonadione
  3. C
    Withhold warfarin and administer prothrombin complex concentrate
  4. D
    Decrease the warfarin dose by 50% and continue daily administration
  5. E
    Continue the current warfarin dose and discontinue levofloxacin

Cevap

Withhold warfarin and monitor the International Normalized Ratio daily
The patient has a supratherapeutic INR of 7.4 without any evidence of clinically significant bleeding. According to current guidelines for the management of supratherapeutic anticoagulation with warfarin, patients with an INR between 4.5 and 10.0 without bleeding should have warfarin withheld for 1 to 2 doses. The INR should be monitored frequently, and warfarin can be resumed at an appropriately adjusted dose once the INR returns to the therapeutic range. Routine administration of oral vitamin K is no longer recommended for this specific INR range due to the risk of overcorrection and prolonged warfarin resistance. This is particularly hazardous in patients with mechanical heart valves who are at a high baseline risk for valve thrombosis if their INR becomes subtherapeutic.

Adım Adım Çözüm

1
Evaluate the patient's current clinical status and laboratory results.
The patient has a significantly elevated INR of 7.4 but is completely asymptomatic with no signs of active bleeding.
The presence or absence of bleeding dictates whether emergent reversal is needed versus conservative management.
2
Identify the likely cause of the supratherapeutic INR.
The recent initiation of levofloxacin is the probable culprit.
Fluoroquinolones inhibit warfarin metabolism and alter gut flora, increasing the anticoagulant effect.
3
Apply guidelines for managing a supratherapeutic INR without bleeding.
For an INR between 4.5 and 10.0 without bleeding, the recommended action is to withhold 1 or 2 doses of warfarin.
Withholding doses allows the INR to drift back to the therapeutic range gradually, avoiding the risk of overcorrection associated with active reversal agents.

Anahtar Kavram

For patients on warfarin who develop an INR between 4.5 and 10.0 without clinically significant bleeding, the most appropriate management is to withhold warfarin and monitor the INR, without administering vitamin K.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru